Skip to main content
. 2021 Mar 12;13(6):1244. doi: 10.3390/cancers13061244

Figure 8.

Figure 8

Alignment of the identified potent KV10.1 hit compound ZVS-08 with the final ligand-based pharmacophore model used for virtual screening (middle), structures of the most active purpurealidin analogue (right) and virtual screening hit compound ZVS-08 (left).